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ABSTRACT 
Introduction: Co-existence type of ESBL-producing isolates are serious problem in the 
public health world.  
Methods Antibiotic susceptibility was determined by disc diffusion and broth microdilution 
according to CLSI guidelines. Double-disk synergy test was performed in order to screen for 
ESBLs/pAmpC beta-lactamases. PCR was used to detect blaESBL/blaampC/blacarb genes. 
Genetic relatedness of the strains was determined by pulsed-field-gel-electrophoresis (PFGE). 
Results In this study 88 of the inpatient isolates (n=126; 10.0%) and 62 of the outpatient 
(n=184; 6.4%) Beta-lactamase-producing isolates were taken for the study. They included 
50.0/29.0% K. pneumoniae, 12.5/30.6% E. coli, 11.4/4.8% A. baumannii, 8.0/14.5% K. 
oxytoca, 8.0/4.8% E. cloacae, 5.7/8.1% Proteus spp., and less than 3.5% of other isolates. Co-
existence of more than two type of beta-lactamases was detected in 77.3% of inpatient and 
45.2% of outpatient isolates. Among inpatient isolates, Klebsiella spp. and E. coli were the 
most frequent isolates which produce more than two type of genes; in ≈ 65% and ≈12% cases. 
Separately, combination of four: TEM+SHV+CTX-M+OXA-1 beta-lactamases in inpatient K. 
pneumoniae isolates were detected in 63.6% cases respectively. Differents in antimicrobial 
resistance were higher to cephalosporins agents in Klebsiella spp., and E. coli at inpatient and 
outpatient isolates which produce more than two types of beta-lactamases than in isolates 
which produce one type of beta-lactamases.  
Conclusion: This work demonstrates a progressively increasing prevalence of co-existence 
type of beta-lactamases expecially in inpatient isolates. Continous monitoring and 
surveillance and proper infection control and prevention practice will limit the further spread 
of these isolates.  
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Introduction 
Most of the genes encoding ESBLs are generally found on plasmids that conferred resistance 
to multiple antibiotic classes and are readily transferable between and within bacterial 
pathogens (1). Family of cefotaxime-beta lactamases (CTX), after SHV-1 and TEM-1, has 
been reported with increasing frequency in the world (2). These genes are commonly found 
with other resistance genes, causing a co-resistance profile inclusive of other non- beta-lactam 
antibiotics such as aminoglycosides and tetracycline (3). 
In recent years the production of more than one beta-lactamase has frequently been reported 
in some countries, such as in the study from India (4,5), China (6), Iran (7), Germany (8), 
Egypt (9), USA (10), Malaysia (11) as well as from Bosnia and Herzegovina (B&H) (12). 
The antimicrobial resistance of Gram-negative bacteria has risen progressively during the last 
decades, leading to an increasing number of outbreaks due to the existence of multi-resistant 
bacteria, especially those producing more than one beta-lactamase type (4). Escherichia coli 
and Klebsiella pneumoniae are major agents and also the most frequent bacteria that produce 
different type of ESBLs. Now it is a serious problem in the world, because the emergence of 
multiple-ESBLs is the important cause of transferable multidrug resistance in Gram-negative 
bacteria (13). 
In the study from Zenica-Doboj Canton (B&H) (2015) co-existence of several ESBL types in 
the same bacterial strain causing in-patient and outpatient urinary tract infections was found 
with prevalence rates of 44.4%/50% in E. coli, 81.8%/30% in K. pneumonia, and 
66.7%/22.2% in K. oxytoca, respectively (12). 
The aim of the study was to investigate a prevalence, antimicrobial characteristics and mode 
of spread of Gram-negative isolates producing more than two different beta-lactamase types 
causing in- and outpatient infections in Zenica-Doboj Canton, B&H.  
Materials and Methods 
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Setting, bacterial isolates and study design 
All consecutive, non-duplicate Gram-negative isolates collected from different specimens and 
resistant to expanded-spectrum cephalosporins from various hospital departments, including 
outpatient department, of the Cantonal Hospital Zenica, B&H, in the period December 2009 – 
May 2010 were included in the study. The Cantonal Hospital Zenica is 849 bed tertiary level 
hospital admitting about 25 000 patients/year, with 240 000 hospital days, and covers a 
population of 331 229 in Zenica-Doboj Canton. 
Institutional review board approval from the Ethics Committee of the Cantonal Hospital 
Zenica was obtained prior to the initiation of the study.  
Detection of ESBLs, plasmid-mediated AmpC β-lactamases and carbapenemases 
A double-disk-synergy test (DDST) using the combination of amoxicillin/clavulanate with 
cefotaxime, ceftriaxone, ceftazidime, and cefepime was performed to detect the production of 
ESBLs (14). Production of ESBLs was confirmed according to CLSI (Clinical and Laboratory 
Standards Institute) combined disk test.  
E. coli, Klebsiella spp., Enterobacter spp., Citribacter spp., Morganella morganii, Proteus 
spp. strains resistant to expanded-spectrum cephalosporins, cefoxitin and beta-lactam 
combinations with inhibitors were screened for the production of AmpC beta-lactamase. 
Production of AmpC beta-lactamase was tested by combined disk test using 3-amino phenyl 
boronic acid (PBA) (15). 
Production of carbapenemases group A or group B was confirmed by combined disk-test 
using EDTA and PBA (16). 
Susceptibility testing 
Susceptibility testing to 12 antimicrobials was performed by a two-fold micro dilution 
technique according to CLSI (Clinical and Laboratory Standards Institute) standard 
procedure: amoxycillin+clavulanic acid (AMC; 20+10 µg), cefazolin (CZ; 30 µg), cefuroxime 
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(CXM; 30 µg), ceftazidime (CAZ; 30 µg),  cefotaxime (CTX; 30 µg), ceftriaxone (CRO; 30 
µg), cefoxitin (FOX; 30 µg), cefepime (FEP; 30 µg), imipenem (IMP; 10 µg), meropenem 
(MEM; 10 µg), gentamicin (GM; 10 µg), and ciprofloxacin (CIP; 5 µg) (14). E. coli ATCC 
25922 (ESBL negative) and K. pneumoniae 700603 (ESBL positive) were used as quality 
control strains. 
PCR detection of blaCTX-M, blaSHV, blaTEM, and blaKPC genes 
PCR was used to detect alleles encoding ESBL enzymes.  
The presence of blaTEM, blaSHV, blaCTX-M genes was investigated by polymerase chain reaction 
(PCR) using primers and conditions as described previously (17).  
 Primers IS26F (5’-GCG-GTA-AAT-CGT-GGA-GTG-AT-3) and IS26R (5’-ATT-CGG-
CAA-GTT-TTT-GCT-GT-3’) were used to amplify 400 bp fragment spanning the link 
between IS26 insertion sequence and blaCTX-M gene in CTX-M producing isolate (18).  
Genes encoding carbapenemases of group A (KPC), group B (MBLs belonging to VIM, IMP 
and NDM family) and OXA-48 were detected by PCR as described previously (16). 
Molecular detection of plasmid-mediated AmpC β-lactamases  
Multiplex PCR with primers specific for MOX, CMY, DHA, ACT, MIR and FOX β-
lactamases was used to detect plasmid-mediated Amp β-lactamases in strains resistant to 
cefoxitin and β-lactam/inhibitor combinations (15). 
Typing by pulsed-field gel electrophoresis (PFGE) of bacterial DNA 
Isolation of genomic DNA, digestion with the XbaI restriction enzyme (Invitrogen) and PFGE 
of the resulting fragments were performed as described by Kaufman et al. (19). The 
electrophoresis was carried out with a CHEF-DRII apparatus (Bio-Rad Laboratories, 
Hercules, CA). The PFGE patterns were compared following the criteria of Tenover et al. (20) 
and analyzed by the GelComparII software (Applied Maths, St Martens, Belgium).  
Results 
 6 
 
ESBL prevalence 
During the period December 2009 – May 2010 a total number of 1254 consecutive, 
nonduplicate in-patient, and 2857 outpatient Gram-negative bacteria were isolated. Among in-
patient samples 126 (10.0%) were beta-lactamase-producing isolates, 40 (31.7%) were from 
urine samples, 35 (27.8%) from surgical wounds, 15 (11.9%) from skin and soft tissue 
infections (SSTIs), 14 (11.1%) from cannula and stoma, 13 (10.3%) from upper respiratory 
tract, 5 (4.0%) from burns, and 4 (3%) from other samples (catheters, ear swabs). 
Among outpatient samples, 184 (6.4%) were beta-lactamase-producing isolates, of which 148 
(80.4%) were from urines, 30 (16.3%) from surgical wounds, and 6 (3.3%) from other 
samples (SSTIs, upper respiratory tract, ear swabs, genital tract, and eyes). 
A total of 88 in-patient and 62 outpatient isolates were available for further analysis including 
44/18 (50.0/29.0%) K. pneumoniae, 11/19 (12.5/30.6%) E. coli, 10/3 (11.4/4.8%) A. 
baumannii, 7/9 (8.0/14.5%) K. oxytoca, 7/3 (8.0/4.8%) E. cloaceae, 5/5 (5.7/8.1%) Proteus 
spp., and 4/5 (3.5%) of other -in/outpatient isolates (C. freundii, M. morganii, and P. 
aeruginosa).  
Most of the 88 ESBL-producing inpatient strains originated from the Pediatric and Neurology 
departments, 29 (33.0%), and 18 (20.5%) isolates.  
The most common beta-lactamase-producing in-patient isolates were K. pneumonia, 44 
(50.0%), and E. coli, 11 (12.5%), followed by 10 A. baumannii, seven K. oxytoca, seven E. 
cloacae, five Proteus spp., three C. freundii, and one P. aeruginosa (11.4%, 8.0%, 8.0%, 
5.7%, 3.4%, 1.1%, respectively). The most common beta-lactamase-producing outpatient 
isolates were E. coli, 19 (30.6%), and K. pneumoniae, 18 (29.0%), followed by nine K. 
oxytoca, five Proteus spp., three E. cloacae, three A. baumannii, two C. freundii, two M. 
morgannii, and one P. aeruginosa (14.5%, 8.1%, 4.8%, 4.8%, 3.2%, 3.2%, 1.6%, 
respectively). 
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Thirty-six (out of 88; 40.9%) isolates were obtained from the in-patients older than 60 years 
of age, followed by the group below one year of age, 25 (28.4%). Duration of hospitalization 
(median) was 14 days; in seven cases duration of hospitalization was in the range 33 to 54 
days. Amoxicillin-clavulanic, gentamicin and cefazolin were mostly used antimicrobials in 
the in-patient infections caused by beta-lactamase-producing isolates, in 39, 23 and 22 
(44.4%, 26.4% and 25.0%) cases, respectively. 
Twenty-seven (out of 62; 43.5%) beta-lactamase-producing isolates were obtained from the 
outpatients older than 60 years of age, followed by children up to one year of age, 16 (25.8%). 
Other data for outpatients were missing. 
 Detection and characterization of β-lactamases  
Among the 88 and 62 beta-lactamase-producing in –and outpatient isolates, respectively, 61 
(69.3%) and19 (30.6%), respectively, were positive for blaCTX-M gene by PCR. 
Sixty-eight (77.3%) in-patient and 29 (46.8%) outpatient isolates co-produced more than two 
genes in different combinations: blaCTX-M, blaTEM-1, blaSHV-1, blaOXA-1, blaDHA-1, or blaCMY-2. 
Forty-five (out of 51; 88.2%) in-patient beta-lactamase-producing Klebsiella spp. (38 K. 
pneumoniae and 7 K. oxytoca) co-produced more than two types of different genes including 
blaCTX-M, blaTEM, blaSHV, blaOXA-1, blaCMY-2 or blaDHA-1 (Tables 1, 2).  
Ten (out of 19; 52.6%) outpatient beta-lactamase-producing E. coli isolates co-produced more 
than two types of beta-lactamases (Tables 1, 2). 
Characterization of carbapenemases 
Carbapenemases were not detected neither by phenotypic nor molecular tests. 
Antibiotic susceptibility 
Isolates with one type of beta-lactamases 
Prevalence of resistance to all cephalosporin antibiotics was noticed among six inpatient 
Klebsiella spp., six Acinetobacter baumanni and seven other isolates (one Citrobacter 
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freundii, two E. coli, three Enterobacter cloacae and one Pseudomonas spp.) ranging from 
14.3-100%. Gentamicin and ciprofloxacin also showed the low activity, 42.9% - 83.3%, 
respectively. Resistance to imipenem and meropenem in Acinetobacter baumanni was noticed 
in 83.3% and 16.7%. 
Nine E. coli and 12 Klebsiella spp. outpatient isolates were resistant to cephalosporins, 
aminoglycosides, fluoroquinolones, with the resistance rates ranging from 25.0% to 100.0%. 
One Acinetobacter baumannii isolate was resistant to imipenem and meropenem (Table 3). 
Isolates with more than two type of beta-lactamases 
ESBL-producing E. coli and Klebsiella spp. inpatient isolates which produced two and more 
than two types of beta-lactamases had higher resistance rates to ceftazidime, cefotaxime, 
ceftriaxone with the range of 50% to 90%, than in isolates which produced one or two types 
of beta-lactamases. The same isolates were resistant to gentamicin and ciprofloxacin (Table 
3). 
In outpatient, ESBL-producing E. coli and Klebsiella spp. isolates, coproducing more than 
two types of beta-lactamases, had higher resistance rates to ceftazidim and ceftriaxone than 
isolates with one type of beta-lactamases (Table 3).  
PFGE typing  
The genetic relatedness was examined trough PFGE typing. Forty-one isolates of K. 
pneumoniae, 18 of E. coli, 11 of Proteus spp., 10 of E. cloacae and six of C. freundii isolates 
were available for the analysis (Figure 1). 
 
Discussion 
In the present study a high prevalence of ESBL-producing isolates which produced two and 
more than two types of beta-lactamases, and their antimicrobial resistance patterns have been 
reported for the first time in the Zenica-Doboj Canton, Bosnia and Herzegovina.  
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CTX-M was the most prevalent gene in inpatient ESBL-producing isolates in this study 
(70%), as it was also reported in some other countries where the prevalence was 96.9% in 
China (5), 80.3% and 91.3% in Germany (8,21),  and 75.5% in Madagascar (22). In 
outpatients TEM was the most prevalent gene (50%). 
The presence of more than two different types of beta-lactamases in the same isolates in this 
study was noticed, 77% in inpatient, and 47% in outpatient. This is similar with the report 
from India, Germany, Malaysia and Iran where the prevalence of coproduction of more than 
two types of beta-lactamases in inpatient was 70%, 77% , 50% and 45% (5,8, 11, 13), 
respectively. These prevalences are lower in the report from China (11%), North Iran (30%), 
and Egypt (10%) (6,7,9).  
Coproduction of more than two types of beta-lactamases was most frequently noticed in 
Klebsiella spp. (66%), which is in concordance with the report from India (70%) (5). This 
result is not in agreement with the findings in Morocco, where E. coli was the most frequently 
noticed (23). 
Isolates obtained in this study, which produced one type of beta-lactamases, showed lower 
prevalence of resistance to cefotaxime, ceftriaxone and ceftazidime than isolates coproducing 
more than two types of beta-lactamases. 
Several distinct PFGE profiles were detected among the inpatient and outpatient ESBL- 
positive strains, indicating that its predominance in our setting was not due to the spreading of 
a single clone, but rather due to the horizontal transfer of plasmids containing genes between 
different species of Enterobacteriaceae. In the hospital environment, under selection pressure, 
plasmids could be transferred between the patients and hospital personnel by hands (11,24). 
The possible explanation for this observation is the fact that ESBLs are encoded on plasmids, 
and therefore, could be easily transmitted as resistance gene elements for other antimicrobials, 
as well as from one organism to another (25). 
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There are many risk factors for colonization or infection with ESBL-producing isolates, such 
as long-term antibiotic exposure, prolonged intensive care unit stay, nursing home residency, 
severe illness, residence in an institution with frequent use of ceftazidime and other third-
generation cephalosporin, and instrumentation or catheterization (25). Correct use of sterile 
gloves, systematic hand decontamination before and after visiting the patients and visitors’ 
restriction are some of isolation measures (26). 
Systematic surveillance of antimicrobial resistance which is the first step toward appropriate 
control of antibiotic usage, does not exist in B&H. Further epidemiological surveillance 
studies are needed in order to provide useful information for prescription of antibiotics and 
their rational use. In addition to this, further studies are needed for a better evaluation of the 
epidemiology of ESBL-producing Gram-negative bacteria causing infections in order to 
develop effective prevention strategies aiming to control the spreading of infections.  
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Table 1. Detection of blaESBL and blaAmpC of the inpatient / outpatient isolates 
Causative 
agent isolated 
Total No 
of the 
inpatient 
–
outpatien
t isolates 
No (%) of the inpatient /outpatient positive isolates   
No of  CTX-M, SHV and AmpC types of the 
inpatient / outpatient isolates 
No of isolates 
co-produced 
more than 2 
genes 
blaTEM-1 blaSHV blaCTX-M blaOXA-1 blaAmpC blaOXA-51 blaKPC/VIM 
Escherichia 
coli 
11/19 
5 (45.5) / 11 
(57.9) 
4 (36.4) /  
4 (21.1) 
8 (72.7) / 10 
(52.6) 
6 (54.5) /  
8 (42.1) 
0 /  
3 (15.8) 
0/0 0/0 
 
SHV-1 (3/4), SHV-5 (1/0), CTX-M-1 (3/2), CTX-M-3 
(1/1), CTX-M-15 (4/7), CMY-2 (0/3) 
 
8/10 
Klebsiella 
pneumoniae 
44 / 18 
33 (75.0) / 7 
(38.9) 
39 (88.6) / 
12 (66.7) 
37 (84.1) / 4 
(22.2) 
17 (38.6) / 
2 (11.1) 
2 (4.5) /  
0 
0/0 0/0 
 
SHV-1 (40/12),CTX-M-1 (11/0), CTX-M-3 (1/0), 
CTX-M-15 (25/3), CTX-M-22 (0/1),  
CMY-2 (2/0), DHA-1 (1/0) 
 
38/8 
Klebsiella 
oxytoca 
7 / 9 
5 (71.4) /  
5 (55.6) 
6 (85.7) / 
1 (11.1) 
5 (71.4) / 
2 (22.2) 
3 (42.9) /  
2 (22.2) 
2(28.6) /  
1 (11.1) 
0/0 0/0 
 
SHV-1 (5/1), SHV-5 (1/0), 
CTX-M-1 (1/0), CTX-M-3 (1/0), CTX-M-15 (2/2)  
CTX-M-28 (1/0), 
CMY-2 (1/1), DHA-1 (1/0),  
 
7/6 
Enterobacter 
cloacae 
7 / 3 
5 (71.4) / 
1  
1 (14.3) / 
1 
3 (42.9) /  
1  
2 (28.6) /  
1  
1 (14.3) /  
0 
0/0 0/0 
 
SHV-1 (1/1), CTX-M-1 (1/0), CTX-M-15 (1/1), CTX-
M-28 (1/0), CMY-2 (1/0) 
 
4/1 
Citrobacter 
freundii 
3 / 2 2 / 0 1 / 0 2 / 0 0/0 0/0 0/0 0/0 
 
SHV-1 (1/0), CTX-M-15 (2/0) 
 
2/0 
Morganella 
morganii 
0 / 2 0/ 1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 
Proteus spp. 5/5 2 / 2 0/0 4 / 1 3 / 1 1 / 1 0/0 0/0 
 
CTX-M-1 (3/1), CTX-M-15 (1/0) 
CMY-2 (1/1) 
 
4/2 
Pseudomonas 
aeruginosa 
1/1 1/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 
Acinetobacter 
baumannii 
10/3 
5 (50.0)/ 
2 
0/0 
2 (20.0)/ 
1 
2 (20.0)/ 
1 
- 
6 (60.0)/ 
1 
0/0 CTX-M-1 (2/1) 5/2 
TOTAL 88/62 
58 (65.9) / 
30 (48.4) 
51 (58.0) / 
18 (29.0) 
61 (69.3) / 
19 (30.6) 
33 (37.5) / 
15 (24.2) 
6 (6.8) /  
5 (8.1) 
6/1 0/0 
SHV-1 (49/18), SHV-5 (2/0) 
CTX-M-1 (21/4), CTX-M-3 (3/1), CTX-M-15 
(35/13),CTX-M-22 (0/1), CTX-M-28 (2/0) 
CMY-2 (4/3), DHA-1 (2/0), 
68/29 
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Table 2. Distribution  of ESBL genotypes in inpatient and outpatient isolates 
Types of beta-lactamases 
E. coli* K. pneumoniae* K. oxytoca E. cloacae* A. baumannii Others* TOTAL* 
in (10) out (14) in (44) out (17) in (7) out (9) in (6) out (2) in (10) out (3) in (8) out (4) in (88) out (62) 
One type: 
TEM 1 3     2  3 1 1 2 7 6 
SHV 1 1 6 9  3  1   1  8 14 
CTX-M            1  1 
CMY-2  1            1 
OXA-51         2    2  
TOTAL: 2 5 6 9  3 2 1 5 1 2 3 17 22 
Two type:               
TEM+SHV   1 4  3       1 7 
TEM+CTX-M           1  1  
SHV+CTX-M 1  4 1         5 1 
CTX-M+OXA-1 2 1     1 1   3  6 2 
CTX-M+CMY-2  1            1 
SHV+DHA-1     1        1  
SHV+CMY-2      1        1 
TEM+CMY-2       1     1 1 1 
TEM+OXA-51         3 1   3 1 
TOTAL 3 2 5 5 1 4 2 1 3 1 4 1 18 14 
Three type:               
CTX-M+SHV+OXA-1 1 1 5  1 2       7 3 
TEM+CTX-M+OXA-1 3 3     1    1 1 5 4 
TEM+CTX-M+CMY-2  1            1 
TEM+SHV+CMY-2     1        1  
CTX-M+OXA-1+CMY-2           1  1  
TOTAL 4 5 5  2 2 1    2 1 14 8 
Three and more than three genes:               
TEM+SHV+CTX-M+OXA-1 1 3 28 3 4  1      34 6 
TEM+CTX-M+OXA-1+OXA-51         2 1   2 1 
TOTAL 1 3 28 3 4  1  2 1   36 7 
 
*Three inpatient and 13 outpatient isolates were phenotypic positive ESBL, but did not show any type of beta-lactamases by PCR. 
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Table 3. Minimum inhibitory concentration (MICs) of various antibiotics for isolates which produce one and  more than two type of 
beta-lactamases 
*amoxicillin/clavulanic, AMC, cefazoline, CZ, cefuroxime, CXM, ceftazidime, CAZ, cefotaxime, CTX, ceftriaxone, CRO , cefoxitin, FOX, cefepime,  
  FEP, imipenem, IPM, meropenem, MEM, gentamicin, GEN,  ciprofloxacin, CIP 
Causative agent 
isolated Setting 
No of 
isolates 
tested 
MIC (mg/L) of antibiotics* 
 AMC CZ CXM CAZ CTX CRO FOX FEP IMI MEM GEN CIP 
Escherichia coli 
Inpatient 
> 2 genes 
8 
(%) of 
resistance 
isolates 
100 100 100 75.0 75.0 87.5 100 62.5 0 0 100 50 
Outpatients 
One gene 
 
Outpatient 
> 2 genes 
9 
 
 
10 
(%) of 
resistance 
isolates 
43.8 100 100 44.4 66.7 66.7 77.7 55.5 0 0 77.7 
 
66.7 
 
            
100 100 100 60.0 60.0 70.0 70.0 10.0 0 0 70.0 60.0 
            
Klebsiella spp. 
Inpatients 
One gene 
 
Inpatient 
> 2 genes 
6 
 
 
45 
(%) of 
resistance 
isolates 
50.0 83.3 53.3 50.0 50.0 83.3 100 50.0 0 0 83.3 
 
66.7 
 
            
100 100 97.8 82.2 84.4 86.7 95.6 53.3 0 0 75.6 55.6 
            
Outpatients 
One gene 
 
Outpatient 
> 2 genes 
12 
 
 
14 
(%) of 
resistance 
isolates 
50.0 100 100 75.0 66.7 58.3 83.3 66.7 0 0 83.3 
 
50.0 
 
            
100 100 100 85.7 64.3 78.6 57.1 28.6 0 0 78.6 57.1 
            
Acinetobacter 
spp. 
Inpatients 
One gene 
 
Inpatient 
> 2 genes 
6 
 
 
5 
(%) of 
resistance 
isolates 
            
100 100 100 100 83.3 83.3 100 66.7 83.3 16.7 66.7 66.7 
            
            
100 100 100 80.0 80.0 100 100 100 100 40.0 100 60.0 
            
Ostalo† 
Inpatients 
One gene 
 
Inpatient 
> 2 genes 
7 
 
 
10 
(%) of 
resistance 
isolates 
            
100 100 71.4 42.9 14.3 42.9 100 14.3 0 0 71.4 42.9 
            
            
100 100 90.0 80.0 90.0 80.0 70.0 70.0 0 0 60.0 80.0 
            
Outpatients 
One gene 
 
Outpatient 
> 2 genes 
12 
 
 
5 
(%) of 
resistance 
isolates 
            
100 100 100 75.0 50.0 100 83.3 25.0 8.3 8.3 100 41.7 
            
            
100 100 80.0 80.0 60.0 80.0 80.0 20.0 40.0 20.0 100 60.0 
            
 18 
 
†Inpatients with one gene: Citrobacter spp-1; E. coli-2; Enterobacter spp.-3; Pseudomonas spp.-1; and >2 genes: Citrobacter spp.-2; Enterobacter spp.-4; Proteus spp.-4 
  Outpatients with one gene: Acinetobacter spp.-1; Citrobacter spp.-2; Enterobacter spp.-3; Morganella morgannii – 2; Proteus spp.-3; Pseudomonas spp.-1; and with >2    
  genes: Acinetobacter spp.-2; Eterobacter spp.-1; Proteus spp.-1. 
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Figure 1-a – Klebsiella pneumoniae 
 
 
Outpatient 
Outpatient 
Outpatient 
Outpatient 
Outpatient 
Outp ti t 
Outp t 
Outp t 
Outpatient 
Outp t 
Outp t 
Out ti t 
Outpatient 
Out ti t 
umbilicus 
umbilicus 
umbilicus 
wound 
wound 
wound 
eyes 
umbilicus 
umbilicus 
    Protocol Gender Sample     Age        Ward           Date       Clonal  
        No                                                                 of isolation  group 
A 
A 
A 
A 
A 
B 
B 
S 
S 
C 
C 
C 
C 
C 
D 
D 
D 
D 
D 
D 
D 
D 
D 
E 
E 
E 
E 
F 
F 
F 
F 
G 
G 
H 
H 
H 
H 
H 
H 
H 
S 
Physiatric 
 20 
 
 
 
 
 
 
Dice (Opt:0.50%) (Tol 3.0%-3.0%) (H>0.0% S>0.0%) [0.0%-100.0%]
PFGE01
1
0
0
9
5
9
0
8
5
8
0
7
5
7
0
6
5
PFGE01
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
M
M
F
M
F
F
M
M
M
F
F
F
F
F
F
M
F
F
urine
urine 
urine
stoma
urine
urine
SSTI
urine
kanila
urine
urine 
urine 
urine
pupak
urine
rana
rana
urine
78
53
02
33
02
27
72
03
39
01
74
67
06
<01
01
70
71
67
Fizijatrija
Interno
outpatients
ORL
outpatients
outpatients
outpatients
Pediatric
ICU
outpatients
outpatients
Interno
outpatients
Pediatric
outpatients
Surgery
outpatients
outpatients
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
27.01.2010.
20.01.2010.
07.04.2010.
26.03.2010.
26.01.2010.
17.02.2010.
04.02.2010.
15.03.2010.
12.04.2010.
23.03.2010.
21.01.2010.
17.02.2010.
07.04.2010.
05.03.2010.
22.02.2010.
01.04.2010.
08.03.2010.
22.01.2010.
 
 
Figure 1-b – Escherichia coli 
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Figure 1-c – Proteus spp. 
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Figure 1-d – Enterobacter cloacae 
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Figure 1-e – Citrobacter freundii 
 
 
Figure 1. Dendograms showing the genetic relatedness of the 86 Enterobacteriaceae isolates. 
Eight (A-H) groups of K. pneumoniae were identified by PFGE typing by using the 80% 
similarity (1-a). Four clones consisted of more than five inpatient and outpatient isolates. 
PFGE typing was not successful in 21 isolates. Six (A-F) groups of E. coli were identified by 
PFGE typing by using the 80% similarity (1-b). Three clones consisted of three isolates in 
each of the  two outpatient and one inpatient isolates. PFGE typing was not successful in 12 
isolates. Four (A-D) groups of Proteus spp. were identified by PFGE typing by using the 80% 
similarity (1-c). Only one consisted of three inpatient isolates. PFGE typing was not 
successful in one isolate. Two (A and B) groups of Enterobacter cloacae were identified by 
PFGE typing by using the 80% similarity (1-d). One clone consisted of six isolates: three 
inpatient and three outpatient isolates. Two (A and B) groups of Citrobacter freundii were 
identified by PFGE typing by using the 80% similarity (1-e). 
ICU, Intensive Care Unit 
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